Indolone Compounds Selective AMPA Receptor Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current AMPA receptor antagonists have narrow therapeutic dosing windows, leading to undesired effects such as ataxia, sedation, and dizziness due to non-selective modulation of AMPA receptors across the central nervous system, and they fail to effectively treat conditions like epilepsy and neurotoxicity with minimal side effects.
Innovation Solution
Development of compounds that selectively modulate TARP γ8-associated AMPA receptor complexes, primarily expressed in the hippocampus and cortex, to achieve therapeutic benefits while minimizing side effects by avoiding modulation of TARP γ2-associated complexes in the cerebellum.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If general AMPA receptor antagonists are used to treat CNS disorders, then therapeutic effects are achieved, but undesired effects such as ataxia, sedation, and dizziness occur due to non-selective modulation
Solution Approach 1:
The patent applies local quality by designing compounds that selectively modulate AMPA receptors in specific brain regions (hippocampus and cortex) rather than uniformly across the entire CNS. The compounds achieve this through selective binding to AMPA receptors associated with TARP γ8, which are predominantly expressed in the hippocampus and cortex, thereby providing region-specific therapeutic effects while sparing other brain areas from unwanted modulation.
Solution Approach 2:
The patent segments the AMPA receptor system by targeting a specific subset of AMPA receptors that are associated with TARP γ8, rather than antagonizing all AMPA receptors. This segmentation allows for selective modulation of hippocampal and cortical circuits involved in epilepsy and neurotoxicity, while leaving cerebellar circuits (associated with TARP γ2) and other brain regions unaffected, thus avoiding ataxia and sedation.
2Reliability
If AMPA receptor activity is inhibited to treat epilepsy, then seizure control is improved, but narrow therapeutic dosing windows limit effective treatment due to overlap with doses causing undesired effects
Solution Approach 1:
The compounds achieve local quality by selectively targeting AMPA receptors in the hippocampus and cortex through TARP γ8 association, which are the primary sites involved in epileptic activity. This regional selectivity allows for effective seizure control at lower doses that do not cause systemic CNS depression, thereby expanding the therapeutic dosing window.
Solution Approach 2:
The patent uses TARP γ8 as an intermediary to achieve selective modulation. The compounds bind to AMPA receptors that are complexed with TARP γ8, which serves as a mediator that confers regional specificity. This intermediary mechanism allows the drugs to selectively affect hippocampal and cortical circuits while sparing other brain regions, enabling effective epilepsy treatment with a wider safety margin.
3Adaptability or versatility
If TARP γ2-associated AMPA receptors are modulated, then broad CNS coverage is achieved, but side effects such as ataxia and sedation increase due to cerebellar and widespread cortical effects
Solution Approach 1:
The patent applies local quality by designing compounds that selectively target AMPA receptors associated with TARP γ8, which are predominantly expressed in the hippocampus and cortex. This regional specificity ensures that therapeutic effects are concentrated in the brain regions most relevant to epilepsy and neurotoxicity, while avoiding modulation of TARP γ2-associated receptors in the cerebellum and other areas, thereby preventing ataxia and sedation.
Solution Approach 2:
The patent segments the AMPA receptor population by targeting only those receptors associated with TARP γ8, rather than modulating all AMPA receptors across the CNS. This segmentation strategy isolates the therapeutic action to hippocampal and cortical circuits, excluding cerebellar circuits from drug effects, thus achieving selective epilepsy treatment without cerebellar side effects.
Data Source
AI summary
Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Formula (I). Also provided herein are pharmaceutical compositions, comprising compounds of Formula (I), and methods of using compounds of Formula (I).